The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
List view / Grid view
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
4 January 2017 | By Niamh Louise Marriott, Digital Editor
Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
1 September 2015 | By Nick Jackson
Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency...
19 August 2015 | By Victoria White
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine's 2015 list of the "World's Most Innovative Companies"...
26 June 2015 | By Victoria White
Alexion has announced that the CHMP of the EMA has adopted positive opinions recommending marketing authorisation of Strensiq and Kanuma...
23 June 2015 | By Victoria White
Alexion Pharmaceuticals has successfully completed its acquisition of Synageva BioPharma, strengthening Alexion's position in devastating and rare diseases...